APPENDIX D	
DETAILED TABLES ON FINANCIAL EFFECTS AND NPV OF NSPS	

		1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
NSP Expenditure	e										
Total Govt NSP E	xpend	-\$8,482,805	-\$9,229,559	-\$9,830,915	-\$10,588,542	-\$11,127,279	-\$12,341,18	6 -\$15,005,665	-\$16,353,751	-\$17,505,049	-\$19,673,115
All NSP Expend		-\$9,573,954	-\$10,412,793	-\$11,438,420	-\$12,493,700	-\$12,992,474	-\$13,896,57	2 -\$17,048,446	-\$18,979,078	-\$20,434,694	-\$22,674,291
HIV Effects - Cas	ses Avoided										
CD4 >500	Diagnosed	544	887	1,369	2,033	2,950	4,213	5,935	8,255	11,320	15,277
CD4 <500	Diagnosed	47	107	210	373	616	1,004	1,573	2,399	3,585	5,266
AIDS	Diagnosed	10	23	44	78	131	192	278	393	540	725
Total Diag. HIV C	Cases Avoided	601	1,017	1,623	2,484	3,697	5,409	7,786	11,047	15,445	21,268
Annual Treatmer	nt Costs-HIV										
CD4>500		\$1,520,716	\$2,479,550	\$3,826,950	\$5,683,119	\$8,246,532	\$11,777,166	\$30,683,950	\$42,678,350	\$58,524,400	\$78,982,090
CD4<500		\$211,430	\$481,341	\$944,687	\$1,677,944	\$2,771,082	\$4,516,505	\$13,612,742	\$20,760,946	\$31,024,590	\$45,571,964
AIDS		\$837,771	\$1,926,874	\$3,686,194	\$6,534,616	\$10,974,805	\$16,085,210	\$13,882,473	\$19,625,223	\$26,965,955	\$36,204,291
Total HIV Costs	Avoided	\$2,569,918	\$4,887,765	\$8,457,831	\$13,895,679	\$21,992,419	\$32,378,880	\$58,179,165	\$83,064,519	\$116,514,945	\$160,758,345
Net Govt Expend	liture/Savings	-\$5,912,888	-\$4,341,794	-\$1,373,084	\$3,307,137	\$10,865,140	\$20,037,694	\$43,173,500	\$66,710,768	\$99,009,896	\$141,085,230
Net All Expend/S	Savings	-\$7,004,036	-\$5,525,028	-\$2,980,589	\$1,401,979	\$8,999,946	\$18,482,308	3 \$41,130,719	\$64,085,440	\$96,080,251	\$138,084,054
HIV	NPV Govt E	xpend @ 5%	All Years	\$2,276,	548,829	NPV All Expend	d @ 5%	All Years	\$2,261,898,701		
			To 2000	\$241,7	02,597			To 2000	\$227,052,469		
	NPV Govt E	xpend @ 3%	All Years	\$3,414,	541,497	NPV All Expend	d @ 3%	All Years	\$3,398,079,560		
			To 2000	\$286,6	31,780			To 2000	\$270,169,843		
	NPV Govt E	expend @ 0%	All Years	\$6,895,	585,578	NPV All Expend	d @ 0%	All Years	\$6,875,779,022		
			To 2000	\$372,5	61 599			To 2000	\$352,755,044		

		1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
HCV Effects - C	ases Avoided										
Stage 0/1	Diagnosed	2,233	2,822	3,419	4,031	4,663	5,321	6,011	6,737	7,505	8,321
Stage 2/3	Diagnosed	132	200	279	372	477	595	727	872	1,031	1,205
Cirrhosis	Diagnosed	3	6	11	18	26	37	51	68	88	112
HCC	Diagnosed	0	0	0	0	0	0	1	1	1	1
Liver Failure	Diagnosed	0	0	1	1	1	2	2	3	4	5
Total Diag. HCV	Cases Avoided	2,368	3,028	3,710	4,422	5,167	5,955	6,792	7,681	8,629	9,644
Whole of HCV E	Episode Costs	\$123,272	\$157,517	\$192,752	\$229,499	\$267,914	\$308,362	\$351,207	\$396,607	\$444,925	\$496,527
Annual Treatme	ent Costs-HCV										
Stage 0/1		\$453,299	\$572,866	\$694,057	\$818,293	\$946,589	\$1,080,163	\$1,220,233	\$1,367,611	\$1,523,515	\$1,689,163
Stage 2/3		\$26,796	\$40,600	\$56,637	\$75,516	\$96,831	\$120,785	\$147,581	\$177,016	\$209,293	\$244,615
Cirrhosis		\$1,140	\$2,280	\$4,180	\$6,840	\$9,880	\$14,060	\$19,380	\$25,840	\$33,440	\$42,560
HCC		\$0	\$0	\$0	\$0	\$0	\$0	\$100,770	\$100,770	\$100,770	\$100,770
Liver Failure		\$0	\$0	\$167,109	\$167,109	\$167,109	\$334,219	\$334,219	\$501,328	\$668,438	\$835,547
Total HCV Cost	s Avoided	\$604,507	\$773,263	\$1,114,736	\$1,297,258	\$1,488,324	\$1,857,589	\$2,173,390	\$2,569,172	\$2,980,381	\$3,409,182
Total Costs Avo	oided HIV + HCV	\$3,174,425	\$5,661,028	\$9,572,567	\$15,192,937	\$23,480,743	\$34,236,46	9 \$60,352,555	\$85,633,691	\$119,495,325	\$164,167,527
Net Govt Expen	diture/Savings	-\$5,308,381	- \$3,568,531	-\$258,349	\$4,604,395	\$12,353,463	\$21,895,28	3 \$45,346,890	\$69,279,940	\$101,990,277	\$144,494,413
Net All Expend/	'Savings	-\$6,399,529	\$4,751,765	-\$1,865,853	\$2,699,237	\$10,488,269	\$20,339,89	7 \$43,304,109	\$66,654,612	\$99,060,631	\$141,493,236
HIV+HCV	NPV Govt	Expend @ 5%	All Years	\$2,401,5		NPV All Expen	ıd @ 5%	All Years	\$2,386,924,875		
	NPV Govt	Expend @ 3%	To 2000 All Years	\$254,85 \$3,653,3	•	NPV All Expen	nd @ 3%	To 2000 All Years	\$240,209,698 \$3,636,862,310		
		•	To 2000	\$301,57		•		To 2000	\$285,114,155		
	NPV Govt	Expend @ 0%	All Years	\$7,678,1	55,690	NPV All Expen	nd @ 0%	All Years	\$7,658,349,135		
		-	To 2000	\$390,82	9,399	·		To 2000	\$371,022,844		

		2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
NSP Expenditure											
Total Govt NSP Expend	I										
All NSP Expend											
HIV Effects - Cases Av	voided										
CD4 >500	Diagnosed	12,681	9,833	7,142	4,896	3,230	2,105	1,363	876	560	356
CD4 <500	Diagnosed	7,551	10,027	12,247	13,901	14,865	15,196	15,094	14,733	14,210	13,603
AIDS	Diagnosed	946	1,219	1,521	1,834	2,130	2,392	2,602	2,746	2,828	2,849
Total Diag. HIV Cases	Avoided	21,178	21,079	20,910	20,631	20,225	19,693	19,059	18,355	17,598	16,808
Annual Treatment Cos	sts-HIV										
CD4>500		\$65,560,770	\$50,836,610	\$36,924,140	\$25,312,320	\$16,699,100	\$10,882,850	\$7,046,710	\$4,528,920	\$2,895,200	\$1,840,520
CD4<500		\$65,346,354	\$86,773,658	\$105,985,538	\$120,299,254	\$128,641,710	\$131,506,184	\$130,623,476	\$127,499,382	\$122,973,340	\$117,720,362
AIDS		\$47,240,358	\$60,873,146	\$75,954,106	\$91,584,372	\$106,365,711	\$119,449,192	\$129,935,953	\$137,126,874	\$141,221,704	\$142,270,380
Total HIV Costs Avoid	ed	\$178,147,482	\$198,483,414	\$218,863,784	\$237,195,946	\$251,706,521	\$261,838,226	\$267,606,139	\$269,155,176	\$267,090,244	\$261,831,262

		2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
HCV Effects - C	ases Avoided										
Stage 0/1	Diagnosed	8,068	7,823	7,586	7,359	7,143	6,937	6,741	6,556	6,379	6,212
Stage 2/3	Diagnosed	1,367	1,516	1,654	1,782	1,901	2,012	2,116	2,213	2,304	2,389
Cirrhosis	Diagnosed	139	170	204	241	281	324	369	416	465	517
нсс	Diagnosed	2	2	3	3	3	4	5	5	6	6
Liver Failure	Diagnosed	6	8	9	11	12	14	16	18	20	22
Total Diag. HC\	/ Cases Avoided	9,582	9,519	9,456	9,396	9,340	9,291	9,247	9,208	9,174	9,146
Whole of HCV I	Episode Costs	\$491,784	\$486,780	\$481,620	\$476,460	\$471,404	\$466,452	\$461,657	\$457,070	\$452,587	\$448,313
Annual Treatme	ent Costs-HCV										
Stage 0/1		\$1,637,804	\$1,588,069	\$1,539,958	\$1,493,877	\$1,450,029	\$1,408,211	\$1,368,423	\$1,330,868	\$1,294,937	\$1,261,036
Stage 2/3		\$277,501	\$307,748	\$335,762	\$361,746	\$385,903	\$408,436	\$429,548	\$449,239	\$467,712	\$484,967
Cirrhosis		\$52,820	\$64,600	\$77,520	\$91,580	\$106,780	\$123,120	\$140,220	\$158,080	\$176,700	\$196,460
нсс		\$201,539	\$201,539	\$302,309	\$302,309	\$302,309	\$403,079	\$503,848	\$503,848	\$604,618	\$604,618
Liver Failure		\$1,002,656	\$1,336,875	\$1,503,985	\$1,838,203	\$2,005,313	\$2,339,532	\$2,673,751	\$3,007,969	\$3,342,188	\$3,676,407
Total HCV Cost	s Avoided	\$3,664,105	\$3,985,612	\$4,241,154	\$4,564,176	\$4,721,738	\$5,148,830	\$5,577,447	\$5,907,075	\$6,338,743	\$6,671,801
Total Costs Avo	oided HIV + HCV	\$181,811,587	\$202,469,026	\$223,104,938	\$241,760,122	\$256,428,259	\$266,987,056	\$273,183,586	\$275,062,251	\$273,428,987	\$268,503,064

		2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
NSP Expendit	ure										
Total Govt NSF	P Expend										
All NSP Expen	d										
HIV Effects - 0	Cases Avoided										
CD4 >500	Diagnosed	225	141	88	55	34	21	13	8	5	3
CD4 <500	Diagnosed	12,958	12,296	11,638	10,996	10,375	9,781	9,214	8,677	8,165	7,679
AIDS	Diagnosed	2,824	2,762	2,674	2,569	2,453	2,331	2,208	2,086	1,968	1,855
Total Diag. HI	V Cases Avoided	16,007	15,199	14,400	13,620	12,862	12,133	11,435	10,771	10,138	9,537
Annual Treatn	nent Costs-HIV										
CD4>500		\$1,163,250	\$728,970	\$454,960	\$284,350	\$175,780	\$108,570	\$67,210	\$41,360	\$25,850	\$15,510
CD4<500		\$112,138,532	\$106,409,584	\$100,715,252	\$95,159,384	\$89,785,250	\$84,644,774	\$79,737,956	\$75,090,758	\$70,659,910	\$66,454,066
AIDS		\$141,021,956	\$137,925,865	\$133,531,413	\$128,288,033	\$122,495,347	\$116,403,038	\$110,260,793	\$104,168,485	\$98,275,924	\$92,633,048
Total HIV Cos	ts Avoided	\$254,323,738	\$245,064,419	\$234,701,625	\$223,731,767	\$212,456,377	\$201,156,382	\$190,065,959	\$179,300,603	\$168,961,684	\$159,102,624

		2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
HCV Effects - Cas	ses Avoided										
Stage 0/1	Diagnosed	6,054	5,905	5,765	5,634	5,511	5,397	5,284	5,173	5,063	4,955
Stage 2/3	Diagnosed	2,469	2,544	2,616	2,683	2,748	2,810	2,867	2,919	2,966	3,008
Cirrhosis	Diagnosed	570	625	682	740	800	862	924	987	1,051	1,115
HCC	Diagnosed	7	8	8	9	10	11	11	12	13	14
Liver Failure	Diagnosed	24	27	29	31	34	36	39	42	44	47
Total Diag. HCV (Cases Avoided	9,124	9,109	9,100	9,097	9,103	9,116	9,125	9,133	9,137	9,139
Whole of HCV Ep	isode Costs	\$444,248	\$440,391	\$436,846	\$433,510	\$430,487	\$427,777	\$424,858	\$421,783	\$418,499	\$415,059
Annual Treatmen	t Costs-HCV										
Stage 0/1	Diagnosed	\$1,228,962	\$1,198,715	\$1,170,295	\$1,143,702	\$1,118,733	\$1,095,591	\$1,072,652	\$1,050,119	\$1,027,789	\$1,005,865
Stage 2/3	Diagnosed	\$501,207	\$516,432	\$531,048	\$544,649	\$557,844	\$570,430	\$582,001	\$592,557	\$602,098	\$610,624
Cirrhosis	Diagnosed	\$216,600	\$237,500	\$259,160	\$281,200	\$304,000	\$327,560	\$351,120	\$375,060	\$399,380	\$423,700
HCC	Diagnosed	\$705,388	\$806,158	\$806,158	\$906,927	\$1,007,697	\$1,108,467	\$1,108,467	\$1,209,236	\$1,310,006	\$1,410,776
Liver Failure	Diagnosed	\$4,010,626	\$4,511,954	\$4,846,173	\$5,180,392	\$5,681,720	\$6,015,939	\$6,517,267	\$7,018,595	\$7,352,814	\$7,854,142
Total HCV Costs	Avoided	\$7,107,030	\$7,711,149	\$8,049,680	\$8,490,380	\$9,100,481	\$9,545,763	\$10,056,364	\$10,667,350	\$11,110,586	\$11,720,166
Total Costs Avoid	ded HIV + HCV	\$261,430,769	\$252,775,568	\$242,751,305	\$232,222,147	\$221,556,858	\$210,702,145	\$200,122,323	\$189,967,953	\$180,072,270	\$170,822,790

		2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
NSP Expenditure											
Total Govt NSP Expend	t										
All NSP Expend											
HIV Effects - Cases Av	voided										
CD4 >500	Diagnosed	2	1	1	0	0	0	0	0	0	0
CD4 <500	Diagnosed	7,219	6,784	6,371	5,980	5,610	5,258	4,925	4,608	4,307	4,021
AIDS	Diagnosed	1,747	1,644	1,546	1,453	1,365	1,281	1,202	1,127	1,056	988
Total Diag. HIV Cases	Avoided	8,968	8,429	7,918	7,433	6,975	6,539	6,127	5,735	5,363	5,009
Annual Treatment Cos	sts-HIV										
CD4>500		\$10,340	\$5,170	\$5,170	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$62,473,226	\$58,708,736	\$55,134,634	\$51,750,920	\$48,548,940	\$45,502,732	\$42,620,950	\$39,877,632	\$37,272,778	\$34,797,734
AIDS		\$87,239,857	\$82,096,351	\$77,202,530	\$72,558,393	\$68,163,941	\$63,969,237	\$60,024,218	\$56,278,946	\$52,733,423	\$49,337,710
Total HIV Costs Avoid	led	\$149,723,423	\$140,810,257	\$132,342,334	\$124,309,313	\$116,712,881	\$109,471,969	\$102,645,168	\$96,156,578	\$90,006,201	\$84,135,444

		2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
HCV Effects - Case	es Avoided										
Stage 0/1	Diagnosed	4,847	4,741	4,635	4,530	4,425	4,321	4,216	4,112	4,007	3,902
Stage 2/3	Diagnosed	3,046	3,079	3,107	3,131	3,149	3,163	3,172	3,176	3,175	3,168
Cirrhosis	Diagnosed	1,179	1,243	1,306	1,369	1,432	1,493	1,552	1,611	1,667	1,721
нсс	Diagnosed	14	15	16	17	18	18	19	20	20	21
Liver Failure	Diagnosed	49	52	55	57	60	62	65	67	69	71
Total Diag. HCV C	ases Avoided	9,135	9,130	9,119	9,104	9,084	9,057	9,024	8,986	8,938	8,883
Whole of HCV Epi	sode Costs	\$411,410	\$407,605	\$403,539	\$399,317	\$394,783	\$390,092	\$385,088	\$379,875	\$374,350	\$368,512
Annual Treatment	Costs-HCV										
Stage 0/1	Diagnosed	\$983,941	\$962,423	\$940,905	\$919,590	\$898,275	\$877,163	\$855,848	\$834,736	\$813,421	\$792,106
Stage 2/3	Diagnosed	\$618,338	\$625,037	\$630,721	\$635,593	\$639,247	\$642,089	\$643,916	\$644,728	\$644,525	\$643,104
Cirrhosis	Diagnosed	\$448,020	\$472,340	\$496,280	\$520,220	\$544,160	\$567,340	\$589,760	\$612,180	\$633,460	\$653,980
HCC	Diagnosed	\$1,410,776	\$1,511,545	\$1,612,315	\$1,713,085	\$1,813,854	\$1,813,854	\$1,914,624	\$2,015,394	\$2,015,394	\$2,116,164
Liver Failure	Diagnosed	\$8,188,361	\$8,689,689	\$9,191,017	\$9,525,236	\$10,026,565	\$10,360,783	\$10,862,112	\$11,196,330	\$11,530,549	\$11,864,768
Total HCV Costs A	Avoided	\$12,060,846	\$12,668,640	\$13,274,778	\$13,713,041	\$14,316,884	\$14,651,321	\$15,251,347	\$15,683,244	\$16,011,699	\$16,438,634
Total Costs Avoid	led HIV + HCV	\$161,784,269	\$153,478,897	\$145,617,112	\$138,022,355	\$131,029,765	\$124,123,291	\$117,896,515	\$111,839,822	\$106,017,900	\$100,574,078

		2031	2032	2033	2034	2035	2036	2037	2038	2039	2040
NSP Expenditure											
Total Govt NSP Exp	end										
All NSP Expend											
HIV Effects - Cases	S Avoided										
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0	0
CD4 <500	Diagnosed	3,750	3,492	3,248	3,016	2,796	2,587	2,388	2,199	2,021	1,851
AIDS	Diagnosed	924	864	806	751	699	650	603	558	516	476
Total Diag. HIV Cas	ses Avoided	4,674	4,356	4,054	3,767	3,495	3,237	2,991	2,757	2,537	2,327
Annual Treatment	Costs-HIV										
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$32,452,500	\$30,219,768	\$28,108,192	\$26,100,464	\$24,196,584	\$22,387,898	\$20,665,752	\$19,030,146	\$17,489,734	\$16,018,554
AIDS		\$46,141,745	\$43,145,528	\$40,249,184	\$37,502,652	\$34,905,930	\$32,459,020	\$30,111,983	\$27,864,820	\$25,767,468	\$23,769,990
Total HIV Costs Av	oided	\$78,594,245	\$73,365,296	\$68,357,376	\$63,603,116	\$59,102,514	\$54,846,918	\$50,777,735	\$46,894,966	\$43,257,202	\$39,788,544

		2031	2032	2033	2034	2035	2036	2037	2038	2039	2040
HCV Effects - Cases A	voided										
Stage 0/1	Diagnosed	3,796	3,690	3,582	3,474	3,364	3,253	3,140	3,026	2,911	2,793
Stage 2/3	Diagnosed	3,157	3,140	3,117	3,089	3,055	3,015	2,969	2,917	2,859	2,794
Cirrhosis	Diagnosed	1,772	1,820	1,865	1,906	1,943	1,975	2,002	2,023	2,038	2,047
HCC	Diagnosed	22	22	23	23	24	24	25	25	25	25
Liver Failure	Diagnosed	74	75	77	79	80	81	82	83	84	84
Total Diag. HCV Cases	Avoided	8,821	8,747	8,664	8,571	8,466	8,348	8,218	8,074	7,917	7,743
Whole of HCV Episode	Costs	\$362,414	\$356,003	\$349,175	\$342,086	\$334,580	\$326,709	\$318,422	\$309,769	\$300,752	\$291,213
Annual Treatment Cos	ts-HCV										
Stage 0/1		\$770,588	\$749,070	\$727,146	\$705,222	\$682,892	\$660,359	\$637,420	\$614,278	\$590,933	\$566,979
Stage 2/3		\$640,871	\$637,420	\$632,751	\$627,067	\$620,165	\$612,045	\$602,707	\$592,151	\$580,377	\$567,182
Cirrhosis		\$673,360	\$691,600	\$708,700	\$724,280	\$738,340	\$750,500	\$760,760	\$768,740	\$774,440	\$777,860
HCC		\$2,216,933	\$2,216,933	\$2,317,703	\$2,317,703	\$2,418,473	\$2,418,473	\$2,519,242	\$2,519,242	\$2,519,242	\$2,519,242
Liver Failure		\$12,366,096	\$12,533,206	\$12,867,424	\$13,201,643	\$13,368,753	\$13,535,862	\$13,702,972	\$13,870,081	\$14,037,190	\$14,037,190
Total HCV Costs Avoid	led	\$17,030,262	\$17,184,232	\$17,602,899	\$17,918,001	\$18,163,202	\$18,303,948	\$18,541,523	\$18,674,262	\$18,802,935	\$18,759,667
Total Costs Avoided H	IV + HCV	\$95,624,507	\$90,549,527	\$85,960,275	\$81,521,117	\$77,265,717	\$73,150,866	\$69,319,258	\$65,569,228	\$62,060,137	\$58,548,211

		2041	2042	2043	2044	2045	2046	2047	2048	2049	2050
NSP Expenditur	re										
Total Govt NSP I	Expend										
All NSP Expend											
·											
HIV Effects - Ca	ses Avoided										
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0	0
CD4 <500	Diagnosed	1,690	1,539	1,395	1,260	1,132	1,013	901	796	699	609
AIDS	Diagnosed	438	402	368	336	305	276	249	224	200	178
Total Diag. HIV	Cases Avoided	2,128	1,941	1,763	1,596	1,437	1,289	1,150	1,020	899	787
Annual Treatme	nt Costs-HIV										
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$14,625,260	\$13,318,506	\$12,072,330	\$10,904,040	\$9,796,328	\$8,766,502	\$7,797,254	\$6,888,584	\$6,049,146	\$5,270,286
AIDS		\$21,872,386	\$20,074,655	\$18,376,799	\$16,778,816	\$15,230,771	\$13,782,599	\$12,434,301	\$11,185,878	\$9,987,391	\$8,888,778
Total HIV Costs	Avoided	\$36,497,646	\$33,393,161	\$30,449,129	\$27,682,856	\$25,027,099	\$22,549,101	\$20,231,555	\$18,074,462	\$16,036,537	\$14,159,064

		2041	2042	2043	2044	2045	2046	2047	2048	2049	2050
HCV Effects - Cases Avoided											
Stage 0/1	Diagnosed	2,674	2,554	2,432	2,308	2,183	2,057	1,930	1,803	1,675	1,548
Stage 2/3	Diagnosed	2,723	2,645	2,561	2,471	2,375	2,272	2,164	2,051	1,933	1,811
Cirrhosis	Diagnosed	2,048	2,042	2,029	2,007	1,976	1,937	1,889	1,832	1,766	1,691
HCC	Diagnosed	25	25	25	25	24	24	23	22	22	21
Liver Failure	Diagnosed	84	83	83	82	80	78	76	74	71	68
Total Diag. HCV	Cases Avoided	7,554	7,349	7,130	6,893	6,638	6,368	6,082	5,782	5,467	5,139
Whole of HCV E	oisode Costs	\$281,310	\$270,990	\$260,252	\$249,098	\$237,578	\$225,642	\$213,393	\$200,884	\$188,061	\$175,082
Annual Treatmer	nt Costs-HCV										
Stage 0/1		\$542,822	\$518,462	\$493,696	\$468,524	\$443,149	\$417,571	\$391,790	\$366,009	\$340,025	\$314,244
Stage 2/3		\$552,769	\$536,935	\$519,883	\$501,613	\$482,125	\$461,216	\$439,292	\$416,353	\$392,399	\$367,633
Cirrhosis		\$778,240	\$775,960	\$771,020	\$762,660	\$750,880	\$736,060	\$717,820	\$696,160	\$671,080	\$642,580
НСС		\$2,519,242	\$2,519,242	\$2,519,242	\$2,519,242	\$2,418,473	\$2,418,473	\$2,317,703	\$2,216,933	\$2,216,933	\$2,116,164
Liver Failure		\$14,037,190	\$13,870,081	\$13,870,081	\$13,702,972	\$13,368,753	\$13,034,534	\$12,700,315	\$12,366,096	\$11,864,768	\$11,363,440
Total HCV Costs	Avoided	\$18,711,574	\$18,491,670	\$18,434,174	\$18,204,109	\$17,700,958	\$17,293,496	\$16,780,313	\$16,262,435	\$15,673,267	\$14,979,143
Total Costs Avoi	ded HIV + HCV	\$55,209,219	\$51,884,831	\$48,883,303	\$45,886,965	\$42,728,057	\$39,842,597	\$37,011,869	\$34,336,897	\$31,709,803	\$29,138,207

		2051	2052	2053	2054	2055	2056	2057	2058	2059	2060
NSP Expenditure											
Total Govt NSP Expend	d										
All NSP Expend											
HIV Effects - Cases A	voided										
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0	0
CD4 <500	Diagnosed	526	451	382	320	265	217	175	139	109	84
AIDS	Diagnosed	157	137	119	103	88	75	63	52	42	34
Total Diag. HIV Cases	Avoided	683	588	501	423	353	292	238	191	151	118
Annual Treatment Co	sts-HIV										
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$4,552,004	\$3,902,954	\$3,305,828	\$2,769,280	\$2,293,310	\$1,877,918	\$1,514,450	\$1,202,906	\$943,286	\$726,936
AIDS		\$7,840,102	\$6,841,363	\$5,942,497	\$5,143,506	\$4,394,452	\$3,745,272	\$3,146,028	\$2,596,722	\$2,097,352	\$1,697,856
Total HIV Costs Avoid	led	\$12,392,106	\$10,744,317	\$9,248,325	\$7,912,786	\$6,687,762	\$5,623,190	\$4,660,478	\$3,799,628	\$3,040,638	\$2,424,792

		2051	2052	2053	2054	2055	2056	2057	2058	2059	2060
HCV Effects - Case	s Avoided										
Stage 0/1	Diagnosed	1,422	1,297	1,176	1,057	942	832	728	631	541	458
Stage 2/3	Diagnosed	1,686	1,559	1,431	1,302	1,175	1,051	930	815	706	605
Cirrhosis	Diagnosed	1,609	1,519	1,423	1,322	1,217	1,110	1,001	894	789	689
HCC	Diagnosed	20	19	17	16	15	14	12	11	10	8
Liver Failure	Diagnosed	64	60	56	52	48	43	39	34	30	26
Total Diag. HCV Ca	ses Avoided	4,801	4,454	4,103	3,749	3,397	3,050	2,710	2,385	2,076	1,786
Whole of HCV Epis	ode Costs	\$162,000	\$148,864	\$135,886	\$122,959	\$110,345	\$98,148	\$86,421	\$75,370	\$64,998	\$55,407
Annual Treatment (Costs-HCV										
Stage 0/1		\$288,666	\$263,291	\$238,728	\$214,571	\$191,226	\$168,896	\$147,784	\$128,093	\$109,823	\$92,974
Stage 2/3		\$342,258	\$316,477	\$290,493	\$264,306	\$238,525	\$213,353	\$188,790	\$165,445	\$143,318	\$122,815
Cirrhosis		\$611,420	\$577,220	\$540,740	\$502,360	\$462,460	\$421,800	\$380,380	\$339,720	\$299,820	\$261,820
НСС		\$2,015,394	\$1,914,624	\$1,713,085	\$1,612,315	\$1,511,545	\$1,410,776	\$1,209,236	\$1,108,467	\$1,007,697	\$806,158
Liver Failure		\$10,695,002	\$10,026,565	\$9,358,127	\$8,689,689	\$8,021,252	\$7,185,705	\$6,517,267	\$5,681,720	\$5,013,282	\$4,344,845
Total HCV Costs Av	voided	\$14,114,740	\$13,247,041	\$12,277,058	\$11,406,200	\$10,535,353	\$9,498,678	\$8,529,878	\$7,498,815	\$6,638,938	\$5,684,018
Total Costs Avoide	d HIV + HCV	\$26,506,845	\$23,991,358	\$21,525,384	\$19,318,987	\$17,223,115	\$15,121,867	\$13,190,356	\$11,298,443	\$9,679,576	\$8,108,811

		2061	2062	2063	2064	2065	2066	2067	2068	2069	2070
NSP Expenditure											
Total Govt NSP Expend	d										
All NSP Expend											
HIV Effects - Cases A	voided										
CD4 >500	Diagnosed	0	0	0	0	0	0	0	0	0	0
CD4 <500	Diagnosed	63	47	35	25	18	12	8	5	2	0
AIDS	Diagnosed	27	21	16	12	8	6	4	2	1	0
Total Diag. HIV Cases	Avoided	90	68	51	37	26	18	12	7	3	0
Annual Treatment Co	sts-HIV										
CD4>500		\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
CD4<500		\$545,202	\$406,738	\$302,890	\$216,350	\$155,772	\$103,848	\$69,232	\$43,270	\$17,308	\$0
AIDS		\$1,348,298	\$1,048,676	\$798,991	\$599,243	\$399,496	\$299,622	\$199,748	\$99,874	\$49,937	\$0
Total HIV Costs Avoid	led	\$1,893,500	\$1,455,414	\$1,101,881	\$815,593	\$555,268	\$403,470	\$268,980	\$143,144	\$67,245	\$0

		2061	2062	2063	2064	2065	2066	2067	2068	2069	2070
HCV Effects - Cases	S Avoided										
Stage 0/1	Diagnosed	383	316	256	204	160	124	94	70	51	36
Stage 2/3	Diagnosed	511	427	349	281	223	173	133	99	73	52
Cirrhosis	Diagnosed	593	504	420	344	277	219	170	130	97	70
HCC	Diagnosed	7	6	5	4	3	3	2	2	1	1
Liver Failure	Diagnosed	22	19	15	12	10	8	6	4	3	2
Total Diag. HCV Cas	ses Avoided	1,516	1,272	1,045	845	673	527	405	305	225	161
Whole of HCV Episo	ode Costs	\$46,598	\$38,728	\$31,535	\$25,280	\$19,963	\$15,481	\$11,832	\$8,809	\$6,463	\$4,587
Annual Treatment C	Costs-HCV										
Stage 0/1		\$77,749	\$64,148	\$51,968	\$41,412	\$32,480	\$25,172	\$19,082	\$14,210	\$10,353	\$7,308
Stage 2/3		\$103,733	\$86,681	\$70,847	\$57,043	\$45,269	\$35,119	\$26,999	\$20,097	\$14,819	\$10,556
Cirrhosis		\$225,340	\$191,520	\$159,600	\$130,720	\$105,260	\$83,220	\$64,600	\$49,400	\$36,860	\$26,600
нсс		\$705,388	\$604,618	\$503,848	\$403,079	\$302,309	\$302,309	\$201,539	\$201,539	\$100,770	\$100,770
Liver Failure		\$3,676,407	\$3,175,079	\$2,506,641	\$2,005,313	\$1,671,094	\$1,336,875	\$1,002,656	\$668,438	\$501,328	\$334,219
Total HCV Costs Av	oided	\$4,835,215	\$4,160,774	\$3,324,439	\$2,662,847	\$2,176,375	\$1,798,176	\$1,326,709	\$962,493	\$670,593	\$484,039
Total Costs Avoided	HIV + HCV	\$6,728,715	\$5,616,188	\$4,426,321	\$3,478,440	\$2,731,643	\$2,201,646	\$1,595,689	\$1,105,637	\$737,838	\$484,039

		2071	2072	2073	2074	2075	Total
NSP Expenditure							
Total Govt NSP Expend	I						-\$130,137,868
All NSP Expend							-\$149,944,423
HIV Effects - Cases Av	voided						
CD4 >500	Diagnosed						96,422
CD4 <500	Diagnosed						344,734
AIDS	Diagnosed						71,410
Total Diag. HIV Cases	Avoided						512,566
Annual Treatment Cos	sts-HIV						
CD4>500							\$470,016,453
CD4<500							\$2,973,533,547
AIDS							\$3,582,173,445
Total HIV Costs Avoid	e d						\$7,025,723,445
Net Govt Expenditure	Savings						\$6,895,585,578
Net All Expend/Saving	JS						\$6,875,779,022

		2071	2072	2073	2074	2075	Total
HCV Effects - Cases A	Avoided						
Stage 0/1	Diagnosed	24	15	9	4	0	285,367
Stage 2/3	Diagnosed	35	23	13	6	0	150,916
Cirrhosis	Diagnosed	48	31	18	8	0	79,585
нсс	Diagnosed	1	0	0	0	0	975
Liver Failure	Diagnosed	1	1	0	0	0	3,248
Total Diag. HCV Case	es Avoided	109	70	40	18	0	520,091
Whole of HCV Episod	le Costs	\$3,075	\$1,981	\$1,147	\$521	\$0	\$22,740,552
Annual Treatment Co	sts-HCV						
Stage 0/1		\$4,872	\$3,045	\$1,827	\$812	\$0	\$57,929,501
Stage 2/3		\$7,105	\$4,669	\$2,639	\$1,218	\$0	\$30,635,948
Cirrhosis		\$18,240	\$11,780	\$6,840	\$3,040	\$0	\$30,242,300
HCC		\$100,770	\$0	\$0	\$0	\$0	\$98,250,451
Liver Failure		\$167,109	\$167,109	\$0	\$0	\$0	\$542,771,360
Total HCV Costs Avo	ided	\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$782,570,112
Total Costs Avoided	HIV + HCV	\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$7,808,293,558
Net Govt Expenditure	e/Savings	\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$7,678,155,690
Net All Expend/Savin	gs	\$301,171	\$188,584	\$12,453	\$5,591	\$0	\$7,658,349,135